Mayo Clinic Laboratory and pathology research roundup: May 24

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT.

COVID-19 vaccines have been associated with a rare life-threatening thrombotic and thrombocytopenic adverse reaction, vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by high levels of platelet-activating anti-platelet factor 4 (PF4) antibodies.

Read more.

Published to PubMed This Week

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.